Associated Papers
Dideoxy Sequencing Enhances Detection of KIT Mutations in Gastrointestinal Stromal Tumors Initially Evaluated by Next-Generation Sequencing Hotspot Panels.
Robinson L et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.
George SL et al.
Cancer Discovery, 2025
A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer.
Rangarajan A et al.
Frontiers in Oncology, 2025
Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research.
Cao L et al.
Global Medical Genetics, 2024
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.
He C et al.
Current Treatment Options in Oncology, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Two different mutational types of familial gastrointestinal stromal tumors: Two case reports.
Wang XK et al.
World Journal of Gastrointestinal Oncology, 2024
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.
Zheng Q et al.
Nature Chemical Biology, 2024
Molecular Profiling of KIT/PDGFRA-Mutant and Wild-Type Gastrointestinal Stromal Tumors (GISTs) with Clinicopathological Correlation: An 18-Year Experience at a Tertiary Center in Kuwait.
Ali RH et al.
Cancers, 2024
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
Tsai HJ et al.
Bmc Cancer, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Genomic profiling in GIST: Implications in clinical outcome and future challenges.
Calderillo-Ruíz G et al.
Neoplasia (new York, N.y.), 2024
Preferential MGMT hypermethylation in SDH-deficient wild-type GIST.
Giger OT et al.
Journal of Clinical Pathology, 2023
Diagnosis, Treatment, and Prognosis of Patients with Primary Familial Gastrointestinal Stromal Tumor: A Case Report and Literature Review.
Yan M et al.
The Oncologist, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S et al.
Acta Neuropathologica, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
A Rare PDGFRA Exon 15 Germline Mutation Identified in a Patient With Phenotypic Manifestations Concerning for GIST-Plus Syndrome: A Case Report and Review of Literature.
Wang C et al.
International Journal of Surgical Pathology, 2023
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor.
Venkataraman V et al.
The Oncologist, 2023
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations.
Villani A et al.
Nature Cancer, 2023
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.
Huang W et al.
Pathology, Research and Practice, 2022
miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs.
Ravegnini G et al.
International Journal of Molecular Sciences, 2022
Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report.
Unk M et al.
Oncology Reports, 2022
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Lyu D et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2022
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group.
Toss A et al.
Current Oncology Reports, 2022
Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors.
Leśniak RK et al.
Acs Medicinal Chemistry Letters, 2022
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Jeffers M et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022
An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors.
Sun Y et al.
Frontiers in Oncology, 2022
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.
Byron SA et al.
Cancer Research, 2021
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.
Steeghs EMP et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021
PDGF receptor mutations in human diseases.
Guérit E et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Gastrointestinal Stromal Tumor in Monozygotic Twins Shows Distinct Mutational Status: A Case Report.
Sobral-Leite M et al.
The American Journal of Case Reports, 2021
KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors.
Palomba G et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ecp), 2021
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Grunewald S et al.
Cancer Discovery, 2021
Mislocalisation of Activated Receptor Tyrosine Kinases - Challenges for Cancer Therapy.
Schmidt-Arras D et al.
Trends in Molecular Medicine, 2020
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke A et al.
Future Oncology (london, England), 2020
Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features.
Lucas CG et al.
Brain Pathology (zurich, Switzerland), 2020
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Banks E et al.
Science Translational Medicine, 2020
GORAB promotes embryonic lung maturation through antagonizing AKT phosphorylation, versican expression, and mesenchymal cell migration.
Liu Y et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2020
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
Serrano C et al.
Bmc Cancer, 2020
Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
Indio V et al.
Frontiers in Immunology, 2020